EUVIMEDEUVIMED entdecken
Crossref

Immunomodulatory antibodies for therapy of cancer

Ingegerd Hellstrom, Min Dai, Karl Erik Hellstrom

HAMDAN MEDICAL JOURNAL · 2014

DOI: 10.7707/hmj.404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HAMDAN MEDICAL JOURNAL, 2014. Verfasst von Ingegerd Hellstrom und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has been known for many years that immunological mechanisms play a key role in cancers, including those which are most common in humans. However, for several decades, the benefit of active immunotherapy was modest. This situation is now rapidly changing. In particular, systemic administration of immunomodulatory monoclonal antibodies (mAbs) has demonstrated clinical efficacy, including complete remission in several patients treated at tolerable toxicity for melanoma or other particular types of tumours.6,7 These findings are remarkable but much remains to be learned.

Zitieren

APA

Hellstrom, I., Dai, M., & Hellstrom, K. E. (2014). Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. https://doi.org/10.7707/hmj.404

Vancouver

Hellstrom I, Dai M, Hellstrom KE. Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. 2014. doi:10.7707/hmj.404

BibTeX
@article{Hellstrom2014,
  author = {Hellstrom, Ingegerd and Dai, Min and Hellstrom, Karl Erik},
  title = {Immunomodulatory antibodies for therapy of cancer},
  journal = {HAMDAN MEDICAL JOURNAL},
  year = {2014},
  doi = {10.7707/hmj.404}
}
Kostenlos starten →